The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Frequent activation of AKT2 kinase in human pancreatic carcinomas
Abstract
Activation of AKT/protein kinase B promotes a variety of biological activities important in tumorigenesis, such as cell survival and cell cycle progression. We previously demonstrated amplification and overexpression of the AKT2 gene in a subset of human pancreatic carcinomas. In this investigation, we assessed AKT2 catalytic activity in 50 frozen pancreatic tissues (37 carcinomas, four benign tumors, and nine normal pancreata) by in vitro kinase assay. Twelve of 37 (32%) pancreatic carcinomas showed markedly elevated levels of AKT2 activity compared to normal pancreata and benign pancreatic tumors. To delineate mechanisms contributing to AKT2 activation in malignant pancreatic tumors, we examined the status of upstream components of the phosphatidylinositol 3‐kinase (PI3K)/AKT pathway. Western blot analysis revealed loss of PTEN protein expression in two of the 12 pancreatic carcinomas with activated AKT2. In vitro PI3K assays demonstrated high levels of PI3K activity in seven carcinoma specimens that showed AKT2 activation. Immunohistochemical staining confirmed high levels of phosphorylated (active) AKT in malignant pancreatic tumors compared to normal pancreata. Overall, these data suggest that upstream perturbations of the PI3K/AKT pathway contribute to frequent activation of AKT2 in pancreatic cancer, which may contribute to the pathogenesis of this highly aggressive form of human malignancy. J. Cell. Biochem. 87: 470–476, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Self-citationGenetic progression in the pancreatic ducts
Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65054-7 · Cited by 373
Cited by
Genetics and biology of pancreatic ductal adenocarcinoma
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,577
Perturbations of the AKT signaling pathway in human cancer
Altomare, D. A., & Testa, J. R. (2005) · Oncogene · doi:10.1038/sj.onc.1209085 · Cited by 1,329
Self-citationPI3K-Akt pathway: Its functions and alterations in human cancer
Osaki, M., Oshimura, M., & Ito, H. (2004) · Apoptosis · doi:10.1023/b:appt.0000045801.15585.dd · Cited by 1,264
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting
(2005) · Advances in Cancer Research · doi:10.1016/s0065-230x(05)94002-5 · Cited by 823
Szafranska, A. E., Davison, T. S., John, J., Cannon, T., Sipos, B., Maghnouj, A., Labourier, E., & Hahn, S. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210228 · Cited by 664
The Akt/PKB pathway: molecular target for cancer drug discovery
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H., & Nicosia, S. V. (2005) · Oncogene · doi:10.1038/sj.onc.1209088 · Cited by 498
Orth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
Biology and management of pancreatic cancer
Ghaneh, P., Costello, E., & Neoptolemos, J. P. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.103333 · Cited by 418
Altomare, D. A., Wang, H. Q., Skele, K. L., Rienzo, A. D., Klein-Szanto, A. J., Godwin, A. K., & Testa, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207721 · Cited by 412
Self-citationRoy, S. K., Srivastava, R. K., & Shankar, S. (2010) · Journal of Molecular Signaling · doi:10.1186/1750-2187-5-10 · Cited by 379
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
NITULESCU, G. M., MARGINA, D., JUZENAS, P., PENG, Q., OLARU, O. T., SALOUSTROS, E., FENGA, C., SPANDIDOS, D. A., LIBRA, M., & TSATSAKIS, A. M. (2016) · International Journal of Oncology · doi:10.3892/ijo.2015.3306 · Cited by 364
Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A., & Karin, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.007 · Cited by 343
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer
Wolpin, B. M., Hezel, A. F., Abrams, T., Blaszkowsky, L. S., Meyerhardt, J. A., Chan, J. A., Enzinger, P. C., Allen, B., Clark, J. W., Ryan, D. P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9514 · Cited by 297
Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions
Balsara, B. R. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh226 · Cited by 295
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas
Stanger, B. Z., Stiles, B., Lauwers, G. Y., Bardeesy, N., Mendoza, M., Wang, Y., Greenwood, A., Cheng, K.-H., McLaughlin, M., Brown, D., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.015 · Cited by 294
Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
Li, X., Zhu, F., Jiang, J., Sun, C., Wang, X., Shen, M., Tian, R., Shi, C., Xu, M., Peng, F., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.026 · Cited by 116
Metadata
- Authors
- Altomare, D. A., Tanno, S., De Rienzo, A., Klein‐Szanto, A. J., Tanno, S., Skele, K. L., Hoffman, J. P., & Testa, J. R.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2002-01
- Volume
- 87
- Issue
- 4
- Pages
- 470-476
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2037524894
- Cited by
- 174
- References
- 3
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.